

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

GRANT OF SHARE OPTIONS

This announcement is made by China Biotech Services Holdings Limited (the “**Company**”, which together with its subsidiaries, the “**Group**”) pursuant to Rule 23.06A of the Rules (the “**GEM Listing Rules**”) Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board (the “**Board**”) of directors (the “**Directors**”, and each a “**Director**”) of the Company is pleased to announce that on 26 November 2020, the Company has granted to an eligible participant of the Company (the “**Grantee**”), subject to acceptance by the Grantee and the payment of HK\$1.00 by the Grantee upon acceptance of the Share Options, 5,000,000 share options (the “**Share Options**”, each a “**Share Option**”) to subscribe for up to a total of 5,000,000 ordinary shares of nominal value of HK\$0.10 each (the “**Shares**”, each a “**Share**”) in the share capital of the Company under its share option scheme adopted on 29 May 2014.

A summary of the grant of the Share Options is set out below:

Date of grant:	12 November 2020 (the “ Date of Grant ”)
Exercise price for each Share Option:	HK\$2.00 per Share for Share Option exercisable from 26 November 2021 to 25 November 2022; HK\$2.10 per Share for Share Option exercisable from 26 November 2022 to 25 November 2023; HK\$2.20 per Share for Share Option exercisable from 26 November 2023 to 25 November 2024;

all of which are higher than:

- (i) the closing price of HK\$1.43 per Share as quoted in the daily quotation sheet of the Stock Exchange on the Date of Grant;

	(ii) the average closing price of HK\$1.334 per Share as quoted in daily quotation sheets of the Stock Exchange for the five business days immediately preceding the Date of Grant; and
	(iii) the nominal value of the Share of HK\$0.10.
Number of Share Options granted:	5,000,000 Shares Options, each Share Option entitling the Grantee to subscribe for one Share
Validity period of the Share Options:	The Share Options are valid commencing from the Date of Grant until the end of the respective exercisable periods, among which: <ul style="list-style-type: none"> (i) 1,665,000 Share Options granted to the Grantee are exercisable from 26 November 2021 to 25 November 2022; (ii) 1,665,000 Share Options granted to the Grantee are exercisable from 26 November 2022 to 25 November 2023; and (iii) 1,670,000 Share Options granted to the Grantee are exercisable from 26 November 2023 to 25 November 2024.

All Share Options were granted to a consultant of the Group.

To the best knowledge, information and belief of the Directors, having made all reasonable enquiry, the Grantee is not a director, chief executive or substantial shareholder of the Company, or an associate (as defined under the GEM Listing Rules) of any of them.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Co-Chairman and Executive Director

Hong Kong, 26 November 2020

As at the date of this announcement, the board of Directors comprises six executive Directors, namely, Mr. Liu Xiaolin (Co-Chairman), Mr. Yao Michael Yi (Co-Chairman), Mr. He Xun, Mr. Huang Song, Mr. Leung Pak Hou Anson and Mr. Wang Zheng; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company information” page of the GEM website at www.hkgem.com for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.